Table 3 Changes in visual acuity.
| Outcome | VISION study year5 Lesion type: all | MARINA8 Lesion type: occult/MC | ANCHOR9 Lesion type: PC | FOCUS10 Lesion type: PC/MC | ||||
|---|---|---|---|---|---|---|---|---|
| 0.3 mg PEG (n = 294) | sham (n = 296) | 0.5 mg RAN (n = 240) | Sham (n = 238) | 0.5 mg RAN + sham PDT (n = 139*) | Sham + PDT (n = 143) | RAN + PDT (n = 105) | Sham + PDT (n = 56) | |
| Mean ± SD no. letters VA at baseline | 52.8±12.6 | 52.7±13.0 | 53.7±12.8 | 53.6±14.1 | 47.1±13.2 | 45.5±13.1 | 45.1±13.8 | 48.5±14.1 |
| 95% CI | 51.4 to 54.2 | 51.2 to 54.2 | 52.0 to 55.3 | 51.8 to 55.4 | 44.9 to 49.3 | 43.4 to 47.6 | 42.5 to 47.7 | 44.8 to 52.2 |
| Loss of <15 letters at 54 weeks5 or 12 months8,9,10 | 206 (70%) | 164 (55%) | 227 (94.6%) | 148 (62.2%) | 134 (96.4%) | 92 (64.3%) | 95 (90.5%) | 38 (67.9%) |
| 95% CI | 64.8 to 75.2 | 49.8 to 61.0 | 91.7 to 97.4 | 56.0 to 68.3 | 93.3 to 99.5 | 56.5 to 72.2 | 84.9 to 96.1 | 55.6 to 80.1 |
| p Value | p<0.001 | p<0.0001 | p<0.001 | p<0.001 | ||||
| Loss of <15 letters at 24 months | 216 (90.0%) | 126 (52.9%) | ||||||
| 95% CI | 86.2 to 93.8 | 46.6 to 59.3 | ||||||
| p Value | p<0.0001 | |||||||
| Gain ⩾15 letters at 54 weeks5 or 12 months8,9,10 | 18 (6%) | 6 (2%) | 81 (33.8%) | 12 (5.0%) | 56 (40.3%) | 8 (5.6%) | 25 (23.8%) | 3 (5.4%) |
| 95% CI | 3.4 to 8.9 | 0.4 to 3.6 | 27.8 to 39.7 | 2.3 to 7.8 | 32.1 to 48.4 | 1.8 to 9.4 | 15.7 to 32.0 | −0.5 to 11.3 |
| p Value | p = 0.04 | p<0.0001 | p<0.0001 | p = 0.003 | ||||
| Gain ⩾15 letters at 24 months | 80 (33.3%) | 9 (3.8%) | ||||||
| 95% CI | 27.4 to 39.3 | 1.4 to 6.2 | ||||||
| p Value | p<0.0001 | |||||||
| Mean change in VA (number of letters) at 54 weeks5 or 12 months8,9,10 | −7.5† | –14.5† | 7.2 | −10.4 | 11.3 | −9.5 | 4.9 (SD 14.7) | −8.2 (SD 16.3) |
| p Value | p<0.002 | p<0.0001 | p<0.0001 | p<0.001 | ||||
| Mean change in VA at 24 months | 6.6 | −14.9 | ||||||
| p Value | p<0.0001 | |||||||
| VA 6/60‡ or worse at baseline | – | – | 31 (12.9%) | 32 (13.4%) | 32 (23.0%) | 46 (32.2%) | 40 (37.7%) | 15 (26.8%) |
| 95% CI | 8.7 to 17.6 | 9.1 to 17.8 | 16.0 to 30.0 | 24.5 to 39.8 | 28.5 to 47.0 | 15.2 to 38.4 | ||
| VA 6/60 or worse at 54 weeks5 or 12 months8,9,10 | 111 (38%) | 165 (56%) | 28 (11.7%) | 102 (42.9%) | 23 (16.4%) | 86 (60.1%) | 31 (29.5%) | 26 (46.4%) |
| 95% CI | 32.2 to 43.3 | 50.1 to 61.4 | 7.6 to 15.7 | 36.6 to 49.2 | 10.4 to 22.7 | 52.1 to 68.1 | 20.8 to 38.2 | 33.4 to 59.5 |
| p Value | p<0.001 | p<0.0001 | p<0.0001 | p = 0.006 | ||||
| VA 6/60 or worse at 24 months | 36 (15.0%) | 114 (47.9%) | ||||||
| 95% CI | 10.5 to 19.5 | 41.6 to 54.3 | ||||||
| p Value | p<0.0001 | |||||||
PC, predominantly classic; MC, minimally classic; PEG, pegaptanib; RAN, ranibizumab; VA, visual; acuity (measured in letters); –, not reported. Numbers are n (%) unless otherwise stated. All p values are for comparison between pegaptanib/ranibizumab treatment arm and control arm. The authors calculated 95% CI where sufficient data were presented in publications.
*Only 139 of the 140 patients were observed at baseline.
†Estimated from graph.
‡The studies included in this systematic review reported Snellen measures in feet, and these have been converted to the UK standard of metres.